Law Daily Report

FDA Approves First Drug-Coated Balloon to Treat Coronary In-Stent Restenosis

  • 📰 Medscape
  • ⏱ Reading Time:
  • 9 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 55%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

The Agent DCB, from Boston Scientific, was superior to uncoated balloon angioplasty for the treatment of coronary artery in-stent restenosis in a pivotal trial.

The US Food and Drug Administration has approved Boston Scientific's Agent Drug-Coated Balloon , the first coronary DCB for the treatment of coronary in-stent restenosis in patients with-coated balloon catheter that transfers a therapeutic dose of the antiproliferative drug to the vessel wall to help prevent in-stent restenosis reoccurrence.

Conducted at 40 sites in the United States, the trial randomly assigned patients with coronary artery in-stent restenosis to the Agent DCB or to conventional balloon

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in LAW

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA Approves First Medication For Treating Allergic Reactions To Multiple FoodsI'm a Chicago-based reporter. My previous experiences include work at Chemical Watch, Becker's Healthcare, Chicago Lawyer Magazine and The Kane County Chronicle. I graduated from DePaul University with degrees in journalism and psychology. Email me at cgleesonforbes.com and follow me on Twitter caileygleeson.
Source: Forbes - 🏆 394. / 53 Read more »